EE351 Estimated Annual Treatment Cost of Hemophilia A Prophylaxis in the United States: Comparison of Jivi® with the Other Extended Half Life (EHL) Factor VIII Products von Malacan, J, Farej, R, Topachevskyi, O

Volltext

EE242 Economic Burden Among Chronic Kidney Disease (CKD) Patients with and without Type 2 Diabetes (T2D) in a Commercially Insured/Medicare Advantage (MA) Population in the United... von Chung, H, Thomas, N, Willey, V, Kong, SX, Singh, R, Farej, R, Williamson, T

Volltext

EPH125 Geographic Disparities in Chronic Kidney Disease Hospitalizations: Exploring Associations with Neighborhood Socioeconomic Status in Texas von Zhong, L, Farej, R, Andreyeva, E, Farag, Y, Singh, R, Kong, SX, Sorescu, A, Ma, P, Du, Y, Udeani, G, Guerrero, G, Ohsfeldt, RL, Young, J, Cameron, J, Williamson, T

Volltext

PSY139 - CURRENT USE OF FACTOR VIII PRODUCTS IN CHILDREN AND ADOLESCENTS WITH MODERATE OR SEVERE HAEMOPHILIA A von Hirst, C., Kessabi, S., Farej, R., Aubert, R., Yao, J., Burke, T., O`Hara, J.

Volltext